Skip to content

Cenobamate

NERVOUS SYSTEM

Also known as: ontozry, xcopri, YKP3089

OnpEMA approvedFDA approvedATC N03AX25

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Cenobamate is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2019. Its mechanism of action is classified as Cytochrome P450 2B6 Inducers, Cytochrome P450 2B6 Inhibitors and Cytochrome P450 2C19 Inhibitors. DrugCentral lists 2 molecular targets, including GABRA4 and GABRA6. Recorded indications include Epilepsy having focal-onset seizures and Partial seizure.

  • Approval status: onp (first approved 2019 by the FDA).
  • Mechanism of action: Cytochrome P450 2B6 Inducers; Cytochrome P450 2B6 Inhibitors; Cytochrome P450 2C19 Inhibitors.
  • Molecular targets: GABRA4 and GABRA6 (2 listed in DrugCentral).
  • Indications: Epilepsy having focal-onset seizures and Partial seizure.
  • ATC code: N03AX25 (Other antiepileptics).
  • Molecular formula: C10H10ClN5O2; molecular weight 267.67 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

  • Epilepsy having focal-onset seizures
  • Partial seizure

Contraindications (1)

  • Genetic short QT syndrome

Mechanism & targets

Mechanism of action (MoA)Cytochrome P450 2B6 Inducers; Cytochrome P450 2B6 Inhibitors; Cytochrome P450 2C19 Inhibitors; Cytochrome P450 2C8 Inducers; Cytochrome P450 3A Inhibitors; Cytochrome P450 3A4 Inducers; GABA A Receptor Positive Modulators; Sodium Channel Antagonists

Molecular targets (2)

TargetGeneActionActivity
Gamma-aminobutyric acid receptor subunit alpha-4GABRA4allosteric modulatorEC50 4.38
Gamma-aminobutyric acid receptor subunit alpha-6GABRA6allosteric modulatorEC50 4.24

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2021-03-26EMA—ARVELLE THERAPEUTICS NETHERLANDS B.V.
2019-11-21FDA—SK LIFE SCIENCE INC

ATC classification

ATC codeTherapeutic hierarchy
N03AX25NERVOUS SYSTEM › ANTIEPILEPTICS › ANTIEPILEPTICS › Other antiepileptics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Seizure1352.5
Somnolence364.1
Product dose omission issue308.7
Drug interaction266.3
Multiple-drug resistance232.9
Off label use179.2
Ataxia138.2
Wrong technique in product usage process136.2
Dizziness132.3
Generalised tonic-clonic seizure126.1
Balance disorder124.3
Seizure cluster120.7

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Cenobamate is on its molecule page.

Molecular formulaC10H10ClN5O2
Molecular weight267.67 g/mol
CAS number913088-80-9
InChIKeyGFHAXPJGXSQLPT-VIFPVBQESA-N
PubChem CID11962412
NC(=O)O[C@@H](CN1N=CN=N1)C1=CC=CC=C1Cl

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Cenobamate used for?

DrugCentral lists the following indications for Cenobamate: Epilepsy having focal-onset seizures and Partial seizure.

How does Cenobamate work?

Cenobamate is classified as Cytochrome P450 2B6 Inducers, Cytochrome P450 2B6 Inhibitors and Cytochrome P450 2C19 Inhibitors; its molecular targets in DrugCentral include GABRA4 (allosteric modulator) and GABRA6 (allosteric modulator).

When was Cenobamate first approved?

Cenobamate was first approved by the FDA in 2019.

What is the chemical formula of Cenobamate?

Cenobamate has the molecular formula C10H10ClN5O2 and a molecular weight of 267.67 g/mol.

Browse: all drugs starting with C · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusONP
First approval2019-11-21
AgencyFDA
Targets2
Indications2
FormulaC10H10ClN5O2
DrugCentral ID5355
Interactive profile